Ipca Laboratories in South Africa

Ipca Laboratories Enhances Global Footprint and Faces Regulatory Challenges

Johannesburg, South Africa – August 3, 2025

Ipca Laboratories, the Indian multinational pharmaceutical company, has recently expanded its global presence and faced regulatory scrutiny, impacting its operations in South Africa.

Acquisition of Unichem Laboratories

In September 2023, Ipca Laboratories increased its stake in Unichem Laboratories to 52.67% through an open offer valued at ₹597.5 crore. This acquisition included Unichem’s subsidiary, Unichem SA Pty, based in South Africa. The move aims to strengthen Ipca’s position in the global pharmaceutical market. (business-standard.com)

Regulatory Scrutiny at Silvassa Facility

In May 2023, the U.S. Food and Drug Administration (FDA) issued a Form 483 with three observations following an inspection of Ipca’s formulations manufacturing unit in Silvassa, India. The observations pertained to quality control and procedural lapses. Ipca committed to addressing these issues promptly. (ndtvprofit.com)

Challenges at Ratlam Facility

In June 2023, the U.S. FDA raised 11 observations regarding Ipca’s active pharmaceutical ingredients (API) manufacturing facility in Ratlam, Madhya Pradesh. The company acknowledged the observations and emphasized its commitment to maintaining high-quality standards. (business-standard.com)

Patent Activity in South Korea

In Q2 2024, Ipca Laboratories reported a 2.99% increase in patent filings in May and a 0.99% increase in grants in April. The South Korea Patent Office accounted for nearly 33% of these filings, indicating a strategic focus on the South Korean market. (pharmaceutical-technology.com)

Closure of South African Subsidiary

In 2016, Ipca Laboratories voluntarily closed its wholly owned subsidiary, National Druggists Pty Ltd., in South Africa. The company cited strategic realignment and operational considerations for this decision. (capitalmarket.com)

Conclusion

Ipca Laboratories continues to navigate the complexities of the global pharmaceutical industry, balancing expansion efforts with regulatory compliance. The company’s activities in South Africa, particularly through Unichem SA Pty, reflect its ongoing commitment to the region.

For more information, visit Ipca Laboratories’ official website at www.ipca.com.